News

Net profit of Beta Drugs rose 35.04% to Rs 15.80 crore in the quarter ended June 2026 as against Rs 11.70 crore during the previous quarter ended June 2025. Sales rose 25.29% to Rs 125.55 crore in the quarter ended June 2026 as against Rs 100.21 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales125.55100.21 25 OPM %21.8019.66 - PBDT26.3919.37 36 PBT22.0415.65 41 NP15.8011.70 35 Powered by Capital Market - Live News

Net profit of Beta Drugs rose 40.19% to Rs 5.93 crore in the quarter ended June 2026 as against Rs 4.23 crore during the previous quarter ended June 2025. Sales declined 15.82% to Rs 55.83 crore in the quarter ended June 2026 as against Rs 66.32 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales55.8366.32 -16 OPM %18.1811.32 - PBDT10.427.69 36 PBT7.935.65 40 NP5.934.23 40 Powered by Capital Market - Live News

Beta Drugs will hold a meeting of the Board of Directors of the Company on 20 July 2026.

Net profit of Beta Drugs rose 0.22% to Rs 9.05 crore in the quarter ended March 2026 as against Rs 9.03 crore during the previous quarter ended March 2025. Sales rose 0.21% to Rs 93.96 crore in the quarter ended March 2026 as against Rs 93.76 crore during the previous quarter ended March 2025.For the full year,net profit declined 2.22% to Rs 41.48 crore in the year ended March 2026 as against Rs 42.42 crore during the previous year ended March 2025. Sales rose 6.20% to Rs 384.83 crore in the year ended March 2026 as against Rs 362.36 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales93.9693.76 0 384.83362.36 6 OPM %18.8218.50 -19.6720.59 - PBDT16.6318.02 -8 71.5574.05 -3 PBT11.8314.45 -18 54.3961.54 -12 NP9.059.03 0 41.4842.42 -2 Powered by Capital Market - Live News

Beta Drugs will hold a meeting of the Board of Directors of the Company on 14 May 2026.